Louis G Lange, MD, PhD, is an internationally recognized expert in the field of molecular mechanisms of cardiovascular disease. He received his BA from the University of Rochester and entered Harvard Medical School in September 1970. In January 1971 he started a reading course with Bert Vallee who encouraged him to pursue an MD/PhD. Lou Lange worked on alcohol dehydrogenase in Bert Vallee’s lab, the Center for Biochemical and Biophysical Sciences and Medicine (CBBSM), from 1972 and received his MD/PhD in 1976. He credits working with Bert Vallee for learning much more than just the science.

After leaving HMS, Dr Lange did a postdoc at the University of Utrecht, and then went to Washington University in 1980. He served as Chief of Cardiology and Professor of Medicine at the Jewish Hospital there from 1985-1992.

In 1992 he left Washington University to start CV Therapeutics. As Chairman, CEO, and Chief Scientific Officer, he oversaw the commercial success of CVT and its sale to Gilead in 2009. Dr Lange is a partner in Asset Management Company, a venture capital firm and also serves as a Senior Advisor of Gilead Sciences, Inc. He has been on the board of and/or founded several other biotech companies in the intervening years, the latest of which is Amygdala Neuroscience.